Senseonics Holdings Inc (SENS) Options

This is going to get real!

Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
October 10 2024 - 4:10PM
PR Newswire (US)
Print
Share On Facebook

Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older

Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year

GERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's first commercial use of Eversense 365, the only CGM to provide one-year of accurate monitoring with minimal interruptions.

Mercy (https://www.mercy.net/newsroom/mercy-quick-facts/), one of the 20 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized quality care and one of the nation’s largest Accountable Care Organizations. Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, children’s, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 900 physician practice locations and outpatient facilities, more than 4,500 physicians and advanced practitioners and more than 47,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. (PRNewsfoto/Mercy)
"This is a pivotal moment for people with diabetes..."

This patient and those who follow, along with their doctors, will be able to monitor glucose levels and trends for a full year, with no requirement for additional sensor replacements and only one calibration per week. Eversense 365 offers patients a truly differentiated CGM experience, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. It also helps people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs that are indicated to last just 10-14 days. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve gylcemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.

"Without the technology, patients deal with constant finger pricks to test their glucose or have sensors that need to be replaced every few days," said Dr. Jeff Ciaramita, Mercy's president of specialty service lines. "This is a pivotal moment for people with diabetes because this groundbreaking technology allows patients a more convenient and reliable way to manage their condition for an entire year with a single sensor. As Mercy strives to make care easy for our patients, what better way than to be the first in the world to offer Eversense 365."

Eversense 365 was approved by the U.S. Food and Drug Administration last month. The commercial launch, which has now begun, is being managed by Senseonics global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE 6523). Mercy serves 3 million patients annually and expects that approximately 30,000 of Mercy's patients could benefit from a CGM system.

"We are thrilled to see the successful first commercial insertion of the Eversense 365 CGM system at Mercy," said Francine Kaufman, M.D. Senseonics' chief medical officer. "Eversense 365 addresses many of the challenges that patients experience with traditional, short-term CGMs and we are excited to see the real-world benefit it can have as it is rolled out to patients across the U.S. We expect that health systems across the country will recognize the benefits that Mercy has embraced and can adopt Eversense 365 towards enhancing the quality of care while reducing the cost of care. Our goal is to make this life-changing technology accessible to as many patients as possible through collaborations with forward-thinking health care leaders such as Mercy."

"This long-term monitoring solution empowers patients with real-time data and enables our clinicians to deliver proactive, personalized care, ultimately leading to better health and quality of life for those we serve," Dr. Ciaramita said. "By adopting Eversense 365, we're enhancing our commitment to value-based care ?driving to improve patient outcomes while reducing overall health care costs."

To learn more about Eversense 365 and for additional information about when the system will be available, go to www.eversensecgm.com. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://provider.eversensecgm.com/contact-us/. Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.

About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com

©2024 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

About Mercy

Mercy, one of the 20 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized care and one of the nation's largest and highest performing Accountable Care Organizations in quality and cost. Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 900 physician practice locations and outpatient facilities, more than 4,500 physicians and advanced practitioners and 50,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2023 alone, Mercy provided more than half a billion dollars of free care and other community benefits, including traditional charity care and unreimbursed Medicaid.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements regarding plans and timing for the commercial launch of the 356-day system, statements regarding the attributes experienced by people with diabetes and differentiating the system from short-term CGM, and statements regarding the experience, potential results and decisions of health care systems, and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the execution of the independent business unit of Ascensia Diabetes Care, the Company's commercialization partner for Eversense, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordinations with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product, uncertainties relating to the current economic environment and such other factors as are set forth in the risk factors detailed in Senseonics' Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and Senseonics' other filings with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

Senseonics Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/mercy-places-first-commercial-eversense-365-the-worlds-first-and-only-365-day-continuous-glucose-monitor-302273383.html

SOURCE Mercy

SENS.......................................https://stockcharts.com/h-sc/ui?s=SENS&p=W&b=5&g=0&id=p86431144783

SENS new 52 week low

So I guess they are taking this one down to zero now.too?

Wall Street Millennial

saw you on the Ballard and FCEL board with the identical message. What's UP?

SENS new 52 week low

SENS new 52 week low

That’s definitely one slanted view.

Apparently the better mouse trap didn’t make it

What happened? I thought the company had a alternative delivery system?

SENS new 52 week low

Price keeps recovering slowly but surely

Sens is ready to skyrocket. No reason why Sens is not $3+.

SenesTech Announces Development and Distribution Agreement for ContraPest® in South Africa
PHOENIX, June 1, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced entry into a Development and Distribution Agreement with Pathogens and Environmental Solutions (PES) of South Africa for the commercialization of ContraPest® into South Africa. Under the agreement, PES will be responsible for seeking regulatory registration, and all marketing and sales of ContraPest into South Africa.


"South Africa is a leading sub-Saharan economy with an active pest control industry focused on the agricultural and public health applications of pest control. We were introduced to South Africa and PES by the South African National Council of SPCAs (NSPCA), who are continuing to advise us, and who clearly articulated their support for fertility control and ContraPest in particular. They have committed to recommend ContraPest to private and state entities and to assist with regulatory issues," said Joel Fruendt, SenesTech's President and CEO.

"NSPCA brought in PES as being an excellent partner for us in this project, as they have extensive experience in securing registration and launching commercialization of pest control products. Specifically, PES is a leading manufacturer and distributor of rodent pest control products, with an explicit goal to constantly grow their range of products by adding innovative products for integrated pest management (IPM)," continued Mr. Fruendt. "While we are starting in South Africa, I have no doubt that we will be able to expand our work with PES across its sub-Saharan territories."

"At PES we aim to bring innovative products to the African Sub-Saharan region. Contrapest fits this aim perfectly, and partnering with Senestech was a logical fit for us at PES, as we are always looking for industry leading products," said Reon Hillebrand, Director at PES. "Once regulatory approval is achieved, we look forward to offering our customers this unique rodent control alternative, complementing our current rodent control offering in South Africa and our other African partners."

About SenesTech
We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the

well, SENS, has been on a mad dash down for the past the ten months.

turning stone

Re: None

Wednesday, December 14, 2022 3:23:30 PM

Post#
215813
of 215813
$5.95akadawson-m

I still have a small number of shares but I will be moving them also. At almost 78 time is not on my side to wait. I was not happy after listening to the latest research crap. a f m d and s e n s are my hope now and I am heavy there. If you are young enough I hope CYDY gets bought up by some other company and you get to make some dollars. I have enjoyed crushing the market over the years and continue to live off of it.

If you’re still in CYDY, I’m all ears.

Okay people TURNING STONE Bought A nice chunk of shares in SENS and I like to talk about the company and what I see ahead for it in my opinion. so I expect some people to come back at me with nice an not so nice comments.

I am. Just waiting for the next pop to sell some short term calls against my LEAPS.

Are you still holding? It just drops and drops

Love this company :) Picked up some last week

Thanks for getting back to me.
I noticed that the 85 cent premium was as high as $1.04 on Monday 8/22 when share price dropped to 1.69. Now that it is back up to $1.85 premium is at 95 cents.
My personal feeling is that the share price is on the right upward path and we will see
$3 or more by Jan as sales increase.
I wish they would advertise on TV like the others are doing. I live in a retirement community and I try to tell people about our CGM all the time. No one has heard of it.

Anyway, thanks for your help. GLTA

You are correct in your strategy. If you sell them at .80 and it closes above the strike you keep the premium. If it closes below it you are put the stock at a cost of 1.70. If it closes ATM you may or may not be put the stock. You could close your contract for a few cents though. Whenever I am put the stock, I then sell covered calls against it until you are called out. Then go back to selling puts.

I typically only sell puts out three months because it takes so long for the premium to decay if you go out longer in time.

Haven't been on the board in awhile.
Just curious what you think of selling Jan 20, 2023 2.5 Puts at 80/85 cents?
Or do you think a different strike price would be a better play?

And just confirming what I think I know.....
If it closes above the strike price on that date, I keep the premium
If it closes below the strike price on that date, I own the stock unless I buy puts back
at whatever price.

What if it closes AT the strike price?

Thanks in advance....

My favorite long term hold.
Holding 2024 2.00 calls at .30
Holding stock at 1.83, selling covered calls against them on pops.

Senseonics Holdings' Elevance Diabetes System Secures Coverage Under Elevance Health; Shares Rise

8/3/22, 11:18 AM
11:18 AM EDT, 08/03/2022 (MT Newswires) -- Senseonics Holdings (SENS) said Wednesday that US insurance company Elevance Health has agreed to provide coverage for the Eversense continuous glucose monitoring system.

The device is designed to continually measure glucose levels in people aged 18 and over with diabetes for up to six months. It is meant to replace fingerstick blood glucose measurements for diabetes treatment decisions.

With the Elevance Health coverage, over 45 million people across 14 states would be able to add the Eversense system to their health plans, Senseonics said.

Shares of the medical technology company were up more than 16% in recent trading activity.

Hold on because there’s more to come Sens is going to go very high this year. Starting 2023 off very great

Sorry I wasn’t able to respond quickly.
That’s decent premium on those May 3.00 puts. They already gained .20 in profit over a week. I think it is still good premium to sell at 1.22. I probably would not buy the May calls unless I was expecting news or an event regarding the company. With the stock trading so low the only calls I’ll buy are LEAPS.

A lot of activity in the May 20th $3 calls and $3 puts. Over 10500 of each.
Calls last price 7 cents
Puts last price $1.42

Is that a certain type of play?
What do you think of just selling those puts?
As always, thanks in advance

I understand your reasoning for going out that long in time. I use this strategy to buy stocks short term but in a case like SENS where it’s a penny stock it’s difficult to collect premium out of the money with short term strikes.

I don’t know the answer to the buyout question. In all the years I’ve been trading that situation has never occurred to me. Probably would be best to ask your broker.

thanks for responding.
What you say makes a lot of sense.
I'm just feeling my way with PUTS, as I have not written too many.
I usually sell covered calls and have enjoyed much success.
But my reasoning for going out so long, is I believe SENS will do well in 6-9 months. So if they put the stock to me at $1.50 then I am using my money for other ventures. I like the company very much,
but their guidance IMO, tells me we need to be patient.

So, my next question to you regards what happens to the put if there is a buyout at say 5 or 6 dollars +/- ? Does the price drop accordingly and gives me the chance to buy it back at much cheaper price, or do they put it to me at $1.50?

Much thanks for your input and education.

My strategy to selling naked puts is short to mid term time frames, typically no longer than 45 days.

thanks for the update.

I have been mulling over writing some Jan 20, 2023 $1.50 puts.
Friday they closed at 54 cents.
Any thoughts?
TIA

Update on Positions. New option position.

I rolled the Jan 2023 2.00 calls into Jan 2024 2.00 calls. It cost me .30/contract to execute this trade.
Option positions
Bought Jan 2024 calls 1.02
Wrote March 4.00 calls .42
When the March calls expire my adjusted cost on the 2024 calls will be .60 (1.02-.42)

Still holding my covered stock
Bought stock 2.25
Wrote March 4.00 calls .42
When the March calls expire the adjusted cost of the stock will be1.83. (2.25-.42)

Brilliant trading. Trading spreads has some advantages but one drawback to buying options outright.
Higher probability of a winning trade.

The stock doesn’t have to move as much, or in some cases not at all to make a profit. Also the stock doesn’t have move as far to make 100% or higher gains. .

You can be wrong about direction and still not lose equity as quickly and salvage losing trade with less losses

A drawback is you are limited on gains

I'm ready to add but I don't know how far would she go any ideas

Thanks again.
I dipped into 3 of those puts at .32 each.
I may go back for 2 more tomorrow at .36 or so.
I believe in the company and think it will rebound. I believe I will make money on these either way, as I wont mind buying them if I have to.
The Jan calls I have I sold 10 at average 75 cents each. So I have a pretty good profit.
Thinking of buying them back and then waiting for spike in price and sell something greater in value but lower in strike price.

Your strategy sounds pretty good and I hope to use it again in some other positions.
GLTA

I like using this strategy to buy stocks after huge sell offs. The volatility is cranked up so the options get super overvalued, increasing the probability of them expiring worthless . It may or may not be a win/win especially if the stock is below 1.70 on expiration.

As far as your Jan 2023 10.00 calls go I would guess your position ( not sure what you paid) is down significantly but don’t have any good advice on them other than to hold or add if you think the stock will make it back to recent heights in a short to medium timeframe. Or dump them if you don’t believe the above scenario.

Thanks for the explanation. Sounds like a win, win.

Heretofore I have only sold covered calls. But writing (selling) a put at this price level sounds pretty good to me. I envision the share price going back up near term, and long term I think we will be richly rewarded.
Always appreciate reading your ideas.
Thanks

I still have my Jan 23 $10 calls. Whats our advice there.
TIA

New here, unfortunately took a starter position just before the FDA news. Why are the '22 projections so low? Any chance they will improve now that they can go to market?

TIA

Wrote 20 March 2.00 puts today at .30.
If SENS closes above 2.00 on March 18 I keep that premium. If SENS closes below 2.00, I’ll own the stock at 1.70 on March 21st.

Probably, be bought out. But no where close to 10.00 pps

I’m holding for sure. This was my long term hold after reading about them awhile back.

Shorts getting burned after hours on Ho,Ok, could the same kind of news happen here and squeeze and burn the recent shorters, anything is possible in the market these days.

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time

February 15, 2022

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.

Management will hold a conference call to review the Company’s fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 2775821, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215006052/en/

Senseonics Investor Contact

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

investors@senseonics.com

Source: Senseonics Holdings, Inc.

<< Back to 2022 News Releases

So…. Whens that buyout?

SENS has provided better care for diabetics and this company will become profitable (IMO). Unfortunately, we have not made money as investors on the good news. The best advice is to hold or accumulate more shares now and wait a year or two for the big payday.

Ascensia issues positive PR


ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS
February 14 2022 - 07:00AM
PR Newswire (US)

PARSIPPANY, N.J., Feb. 14, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.
Ascensia Diabetes Care logo

Robert Schumm, President at Ascensia Diabetes Care, said, "As the world's first and only long-term CGM System, Eversense is truly innovative and the prospect of using a single sensor for 6 months is a huge step forward for people with diabetes. Ensuring that as many people as possible have access to Eversense E3 is key for us and we'll be introducing a program to help users experience Eversense affordably as we work closely with payers on coverage. We look forward to rolling out this next-generation system through our dedicated CGM commercial team in the U.S. in the coming months, as we strive to improve the lives of people with diabetes everywhere."

Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System, which includes a sacrificial boronic acid (SBA) design modification to enhance sensor survival, offers patients:

The longest lasting CGM available, with 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year
Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% demonstrated in the PROMISE Study1 for the duration of sensor wear
A fully implantable fluorescence-based sensor, with a removable smart transmitter* that provides discreet on-body vibratory alerts and transmits data to a mobile app
Fewer calibrations, with primarily one calibration required per day after day 21 of use

"This next generation system delivers on the patient's desire for a CGM sensor that is both long-lasting and highly accurate," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Its unique features and benefits offer people with diabetes unparalleled flexibility, convenience and accuracy. Our partner Senseonics has designed Eversense E3 with the user in mind and we are excited to bring the system to people in the U.S. in the second quarter."

To be among the first to know when Eversense E3 is commercially available, patients who are interested in getting started with Eversense now can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at www.ascensiadiabetes.com/eversense/become-a-provider/register/. Alternatively, contact 844-SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.

* There is no glucose data generated when the transmitter is removed.
1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

View original content:https://www.prnewswire.com/news-releases/ascensia-diabetes-care-announces-fda-approval-of-the-eversense-e3-continuous-glucose-monitoring-system-for-use-for-up-to-6-months-301481042.html

SOURCE Ascensia Diabetes Care

Copyright 2022 PR Newswire

Taking bids. To buy SENS or to sell Sens. If it’s good news I buy it goes down. If it goes down i buy it goes lower So for the right bid I will either buy or sale on your request